PharmaShots | Incisive News in 3 Shots

Subscribe Now

tyvyt

Innovent Reports Results of Tyvyt + Byvasda (biosimilar- bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC

Innovent Reports Results of Tyvyt + Byvasda (biosimilar- bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC

November 23, 2020

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

September 28, 2020

Lilly and Innovent Report the Global Expansion of their Alliance for Tyvyt (sintilimab)

Lilly and Innovent Report the Global Expansion of their Alliance for Tyvyt (sintilimab)

August 18, 2020

Innovent and Eli Lilly Report sNDA Acceptance of Tyvyt (sintilimab) Combination Regimen as 1L Therapy in Squamous Non-Small Cell Lung Cancer in China

Innovent and Eli Lilly Report sNDA Acceptance of Tyvyt (sintilimab) Combination Regimen as 1L Therapy in Squamous Non-Small Cell L...

August 12, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us